NCT02936934

Brief Summary

The objective of this study is compare adverse reactions associated with oxycodone and morphine for the treatment of postoperative pain after abdominal hysterectomy

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Oct 2016

Shorter than P25 for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2016

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

October 14, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 18, 2016

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2017

Completed
Last Updated

October 18, 2016

Status Verified

October 1, 2016

Enrollment Period

2 months

First QC Date

October 14, 2016

Last Update Submit

October 14, 2016

Conditions

Keywords

Adverse Drug ReactionMorphineOxycodoneAbdominal hysterectomy

Outcome Measures

Primary Outcomes (1)

  • Adverse drug reactions (questionnaire)

    Nausea, vomiting, respiratory depression, dizziness, headache, sedation, pruritus and anaphylaxis

    24 hours

Secondary Outcomes (4)

  • Postoperative pain (Numeric Pain Rating Scale)

    24 hours

  • systemic blood pressure (mmHg) (physiological parameter)

    24 hours

  • Heart rate (physiological parameter)

    24 hours

  • Oxygen saturation (physiological parameter)

    24 hours

Study Arms (2)

Morphine

ACTIVE COMPARATOR

Multimodal analgesia to morphine

Drug: Morphine

Oxycodone

EXPERIMENTAL

Multimodal analgesia to oxycodone

Drug: Oxycodone

Interventions

Interventions pre-specified to be administered to participants: Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery Intravenous infusion: 200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours

Morphine

Interventions pre-specified to be administered to participants: Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery Intravenous infusion: 150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours.

Oxycodone

Eligibility Criteria

Age30 Years - 55 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients scheduled for abdominal hysterectomy
  • Signing for informed consent

You may not qualify if:

  • Patients used with MAO inhibitor drugs (\<14 days before surgery)
  • History of substance abuse
  • Hypersensitivity to opioids and others drugs of multimodal analgesia (metamizol and lidocaine)
  • Pretreatment of any opioid (\<7/2 lives of the drug in question)
  • Chronic pain of any etiology (\> 6 months)
  • Diagnosis of bowel obstruction
  • Renal or hepatic insufficiency
  • Asthma, chronic obstructive pulmonary disease (COPD), and/ or hypothyroidism.
  • Patients requiring general anesthesia for surgical complications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pain, PostoperativeDrug-Related Side Effects and Adverse Reactions

Interventions

MorphineOxycodone

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and SymptomsChemically-Induced Disorders

Intervention Hierarchy (Ancestors)

Morphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsCodeine

Central Study Contacts

VIRGINIA A SANCHEZ, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD Pharmacology

Study Record Dates

First Submitted

October 14, 2016

First Posted

October 18, 2016

Study Start

October 1, 2016

Primary Completion

December 1, 2016

Study Completion

February 1, 2017

Last Updated

October 18, 2016

Record last verified: 2016-10

Data Sharing

IPD Sharing
Will not share